MNKD logo

MNKD
Mannkind Corp

41,962
Mkt Cap
$1.16B
Volume
20.39M
52W High
$6.51
52W Low
$2.23
PE Ratio
-48.33
MNKD Fundamentals
Price
$3.77
Prev Close
$3.64
Open
$3.66
50D MA
$2.87
Beta
0.84
Avg. Volume
3.59M
EPS (Annual)
$0.0187
P/B
-19.67
Rev/Employee
$589,469.59
$2,083.05
Loading...
Loading...
News
all
press releases
S&P 500 Jumps For Ninth Week, Longest Since 2023 With DELL Leading Nasdaq To Record Highs, While Positive US-Iran Ceasefire Bets Aid Dow — UMG, COIN, MNKD, ASTC, ASTS In Focus
President Donald Trump said he was ready to make a “final determination” on a preliminary agreement to extend the ceasefire.
Stocktwits
News Placeholder
More News
News Placeholder
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children
U.S. Food and Drug Administration (FDA) has approved Afrezza Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.
Stocktwits
News Placeholder
MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes Treatment
The FDA set a PDUFA action date for MannKind’s Afrezza inhaled insulin therapy for children and adolescents with diabetes.
Stocktwits
News Placeholder
UTHR Holds As Tyvaso Shows 33% Lower Worsening Risk In Rare Lung Scarring Disease
UTHR Holds As Tyvaso Shows 33% Lower Worsening Risk In Rare Lung Scarring Disease
Stocktwits
News Placeholder
The $59B Quiet Shift Reshaping How Patients Access Care
The $59B Quiet Shift Reshaping How Patients Access Care The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026 Issued on behalf of VentriPoint Diagnostics...
PR Newswire
News Placeholder
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
News Placeholder
MannKind (MNKD) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of -150.00% and -13.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
MannKind (NASDAQ:MNKD) Shares Gap Up - Should You Buy?
MannKind (NASDAQ:MNKD) Shares Gap Up - Should You Buy...
MarketBeat
News Placeholder
MNKD Stock Records Biggest Single-Day Gains In Over 5 Years, Breaches A Key Technical Milestone – What’s Driving This Rally?
MannKind is developing a dry powder inhalation version of a drug to treat pulmonary arterial hypertension.
Stocktwits
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available